Quantcast

Latest Trastuzumab Stories

2014-02-03 08:27:04

INCLINE VILLAGE, Nev., Feb. 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into an agreement with Genentech, Inc. (Genentech) and F. Hoffmann-La Roche Ltd. (Roche) which resolves all outstanding legal disputes between the parties, including its Nevada litigation with Genentech and Roche and its arbitration proceedings with Genentech related to the audit of royalties on sales. (Logo:...

2014-02-03 00:21:09

Availability of 150 mg formulation increases dosing convenience and flexibility MUMBAI and PITTSBURGH, Feb. 3, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India. The product, which will be marketed by Mylan under the brand name Hertraz(TM), is a biosimilar to Roche's...

2014-01-22 23:25:28

PhenoPath is one of the first labs in the US to adopt all the complex changes of the 2013 ASCO-CAP HER2 Testing Guideline updates in breast cancer. Seattle, WA (PRWEB) January 22, 2014 PhenoPath is one of the first labs in the US to adopt all the complex changes of the 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO-CAP) HER2 Testing Guideline updates in breast cancer. PhenoPath offers both IHC and FISH—including options for alternative Chromosome...

2014-01-13 12:26:52

WORCESTER, Mass. and TORONTO, Jan. 13, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced completion of enrollment of the Antigen Express, Inc. (www.antigenexpress.com) AE37 breast cancer immunotherapy trial. The clinical trial is designed to assess the ability of AE37 to reduce the risk of relapse in patients who have had breast cancer. While a pre-planned primary efficacy analysis is underway, completion of enrollment sets the...

2014-01-09 12:26:12

Company Representatives will also attend the 32nd Annual J.P. Morgan Healthcare Conference next week in San Francisco WORCESTER, Mass. and TORONTO, Jan. 9, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that Dr. Eric von Hofe, PhD, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be a keynote speaker at IBC's 16(th) Annual TIDES Conference (www.IBCLifeSciences.com/Tides) to...

2014-01-06 08:27:53

WORCESTER, Mass. and TORONTO, Jan. 6, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced the database lock for the primary efficacy analysis of its ongoing AE37 breast cancer vaccine trial. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). A previously released positive interim analysis showed a strong trend toward reduced...

2013-12-14 23:00:56

MarketResearchReports.Biz announces addition of new report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” to its database. Visit: http://www.marketresearchreports.biz/analysis-details/monoclonal-antibodies-market-in-gastric-and-esophageal-cancers-to-2019-crowded-late-stage-pipelines-and-favorable-market-conditions-encourage-robust-growth. Albany, NY (PRWEB) December 14, 2013...

2013-12-12 10:59:30

98.7 percent are cancer free for at least 3 years A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found. The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+. Results were presented during the 2013 San Antonio Breast Cancer...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related